# XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

> **NCT02350686** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 67 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT02350686
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05-14
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02350686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02350686, "XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02350686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*